Senses Disorder TRIZ Cases

Anti-IgD antibodies bind surface membrane IgD to inhibit Th1 cytokine expression, reducing autoimmune disease risks.

A proline-rich protein 4 derived peptide inhibits nerve cell death through specific amino acid sequences.

Segmented polyurethane microparticles eliminate initial burst delivery by tailoring degradation rates through parameter changes.

Disrupting cis RGMa and Neogenin interactions via lipid raft modulation promotes axon regeneration in central nervous system injuries.

Plasmin degrades vitreous laminin and fibronectin, enabling therapeutic agents to permeate ocular structures blocked by intravitreal injection limitations.

Modulating p190RhoGAP resolves the contradiction between effective angiogenesis treatment and complex signaling pathways by targeting specific intermediaries.

Indacene sulfonylureas inhibit NLRP3-dependent processes to reduce systemic inflammation without causing immunosuppressive side effects.

Antibodies bind misfolded transthyretin to reduce fibril formation, addressing inadequate treatments for amyloidosis.

N-phenylanthranilic acid compounds modulate potassium ion flux through KCNQ2 and KCNQ3 channels, resolving selectivity issues found in prior Kv7 modulators.

A polysaccharide-based polymer compound releases hydrogen sulfide through thiol activation.

Linagliptin reduces oxidative stress and prevents diabetic complications by addressing endothelial dysfunction independently of glycemic control.

ROCK2-selective compounds reduce fibrosis and regenerate neurons without hyperemia, resolving the trade-off between efficacy and side effects.

Composite lipid-polymer particles deliver insoluble cannabinoids, resolving stability and bioavailability trade-offs in ophthalmic treatments.

Modified siRNA silences TRPV1 mRNA, overcoming short action duration of chemical inhibitors.

Müller glial cells differentiate into rod photoreceptors through targeted gene activation.

Covalent bonding of aminoalkyl cinnamate to hyaluronic acid resolves the contradiction between objective reliability and patient compliance.

Cryo-milling single chain antibodies with hexylsubstituted poly(lactic acid) creates a stable, low-viscosity injectable formulation.

Benzyl amine compounds modify molecular structure to target the glucocorticoid receptor, reducing undesirable metabolic actions.

Neutralizing antibodies target RGMa to restore barrier integrity and suppress granulocyte infiltration, addressing unmanaged pain in acute neuromyelitis optica.

Non-proteinaceous stabilizers preserve botulinum neurotoxin activity, avoiding pathogen risks from mammalian proteins.

Halofuginol derivatives modify chemical parameters to reduce toxicity while maintaining biological activity against chronic inflammatory diseases.

Carboxymethyl cellulose increases ketorolac bioavailability by over 200% while reducing ocular surface toxicity and irritation.

Morpholino pyrido[3,2-d]pyrimidine derivatives achieve isoform selectivity by applying local quality and parameter changes to the core scaffold.

Truncated linear peptides enable corneal penetration and sustained receptor activation, resolving bioavailability limits of full-length natriuretic peptides.

Gallate compounds solubilize insoluble therapeutics in aqueous environments, resolving delivery bottlenecks without adding complex carrier polymers.

Snake venom basic protease inhibitors resolve hepatotoxicity trade-offs by delivering selective vasopressin-2 receptor blockade with enhanced bioavailability.

Modular HIF-1α inhibitor compounds suppress VEGFA expression to reduce cancer cell growth while minimizing synthesis complexity.

Segmented triterpenoid scaffolds with local quality modifications enhance biological activity while managing structural diversity.

Substituted heteroaryl fused derivatives address inadequate existing agents by effectively modulating phosphoinositide 3-kinase activity.

Specific 6-oxo-1,6-dihydropyridazine derivatives block the MAP kinase pathway to treat hyperproliferative diseases.

Topical plant extract combination restores crystalline lens elasticity, replacing invasive surgery risks with non-invasive near vision improvement.

Specific compounds inhibit store-operated calcium channels by binding to STIM and Orai proteins.

A polynucleotide cassette with a human retinal arrestin 3 promoter directs hCNGA3 expression to cone photoreceptor cells.

Zwitterionic polysaccharide conjugates induce antigen-specific regulatory T cells through direct cell contact.

Collagen hydrolysate boosts mitochondrial activity and lipid catabolism, addressing inadequate endurance enhancement from standard supplements.

Recombinant AAV vectors deliver anti-VEGF coding sequences to target tissues.

Oral resveratrol composition reduces VEGF levels to extend injection intervals and minimize ocular side effects.

New TRPM8 antagonist compounds block the receptor to prevent desensitization, providing sustained relief from migraines and neuropathic pain.

Delta-six desaturase enzymes convert linoleic acid into gamma-linolenic acid in transgenic safflower seeds, achieving 45-60% concentration.

Segmenting the dCas9-KRAB complex resolves viral vector size limits while maintaining targeted VEGF silencing efficacy.

Topical perchlorate anion blocks sodium-iodide symporter activity to prevent nasolacrimal duct obstruction.

Cicaprost prodrugs extend half-life via metabolic conversion, resolving the trade-off between therapeutic efficacy and duration of action.

Sulglycotide eye drops stimulate lacrimal glands to boost tear production while reducing inflammatory cytokines that damage the ocular surface.

Aggregated AAV formulations in the suprachoroidal space prolong residence time and increase transgene expression rates.

2-oxo-1-pyrrolidine derivatives address limited therapeutic options by treating epilepsy, Parkinson's disease, and chronic pain via modular synthesis.

A nutraceutical ophthalmic composition combining vitamins, trace elements, carotenoids, omega-3 fatty acids, and resveratrol.

A donor template and DNA nuclease enable transgene insertion into a safe harbor gene within human neural stem cells.